ScholarIQanswers from OpenAlex

Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study

PaperCitations, authors & open-access status

Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study have?

ScholarIQcitation count

Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study has 0 citations in the OpenAlex counts ScholarIQ stores.

When was Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study published?

ScholarIQyear

Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study has 2025 year in the ScholarIQ index.

What is the open-access status of Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study?

ScholarIQoa status

Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study has bronze oa status in the ScholarIQ index.

What is the DOI of Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study?

ScholarIQdoi

The DOI for Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study is on the source record.

What is the OpenAlex record for Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study?

ScholarIQopenalex

The OpenAlex for Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial